Extended Data Fig. 1: Study design.
From: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial
Study design showing the main study and fibrate cohorts as randomized. The 6-week screening period consisted of a 4-week medication/lifestyle stabilization period followed by a 1- to 2-week TG qualification period. EOS, end of study; EOT, end of treatment; MRI-PDFF, magnetic resonance imaging whole liver proton density fat fraction; TG, triglycerides; QW, once weekly; Q2W, once every 2 weeks.
